Goldman Sachs Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $139
Truist Financial Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $90
Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
BioMarin Pharmaceutical Projects Strong Growth Through 2034
Express News | Biomarin Pharmaceutical Inc: Reaffirming Its Long-Term Financial Guidance and Outlook That It Presented During Investor Day
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today